Medaimun presented recent findings of the Omalizumab dose extension trail in patients with high levels of IgE the ERS in Vienna 2009
Medaimun finished successfully the dose extension trail of Omalizumab (Xolair) in patients with high levels of IgE. This FDA approved trial, initiated by Novartis Pharma GmbH was a randomized, double-blind, placebo-controlled study to demonstrate the efficacy of Xolair in an allergen bronchoprovocation study in asthmatic populations defined by serum IgE concentrations. We demonstrated for the first time that Omalizumab efficiently blocks the allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma with high pre-treatment IgE levels (700–2000 IU/mL).
• Download Protection against bronchoconstriction_ERS2009
Preliminary data of a sub-study by Medaimun showed that Omalizumab (Xolair) is fully effective at week four by blocking the EAR and LAR after allergen challenge. Interestingly the LAR was earlier blocked than the EAR (2 weeks vs. 4 weeks). Moreover, the fall of eNO-values indicates a significant improvement of allergen-induced airway inflammation.
These interesting data were presented as an outstanding poster on the international congress of the European Academy of Allergology and Clinical Immunology (EACCI) in Warsaw, Poland 2009
Originated from the children allergy and pneumology department of the Johann Wolfgang Goethe University Frankfurt a new start-up company, Medaimun was launched at September 25th. Numerous guests joined Medaimun‘s opening ceremony ranging from science to business. Special guests were Mr. Johann Wolfgang Goethe and Dr. Johann Christian Senckenberg.
|
